QUEBEC CITY, Feb. 22 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage
drug development company specialized in oncology and endocrinology,
announced today that it has filed a prospectus supplement dated
February 22, 2011 to its U.S.
shelf prospectus, dated March 12,
2010, forming part of its U.S. registration statement on
Form F-3 with the United States Securities and Exchange Commission
("SEC") as well as a prospectus supplement to its Canadian final
base shelf prospectus dated March 12,
2010.
Aeterna Zentaris has entered into an "At-the-Market" ("ATM")
Sales Agreement, dated February 22,
2011, with McNicoll, Lewis & Vlak LLC ("MLV"), under
which the Company may, at its discretion, from time to time during
the 24-month term of the agreement, sell up to a maximum of
12,500,000 of its common shares through ATM issuances on the NASDAQ
Stock Market not to exceed US$19.8
million, being the aggregate amount remaining available for
distribution under the Company's current F-3 registration
statement. MLV will act as sales agent for any sales made under the
ATM. The common shares will be sold at market prices prevailing at
the time of a sale (if any) of the common shares, and, as a result,
prices may vary. The Company is not required to sell any of the
reserved shares at any time during the term of the ATM.
The U.S. shelf prospectus and the supplement thereto have been
filed with the SEC on the SEC's website (www.sec.gov) and the
Canadian final base shelf prospectus and the supplement thereto
have been filed on the SEDAR website maintained by the Canadian
Securities Administrators at www.sedar.com. Alternatively,
MLV will provide copies of the U.S. documents upon request by
contacting McNicoll, Lewis & Vlak LLC, Attention: Randy Billhardt, 420 Lexington Avenue,
New York, NY 10170, or by calling
212-580-5881, while copies of the Canadian documents may be
obtained by contacting the Company's Investor Relations department
directly by calling (418) 652-8525, ext. 265.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the common
shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, ovarian, endometrial cancer and
multiple myeloma. The Company's innovative approach of
"personalized medicine" means tailoring treatments to a patient's
specific condition and to unmet medical needs. Aeterna Zentaris'
deep pipeline is drawn from its proprietary discovery unit
providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
Copyright . 22 PR Newswire